Bullous Pemphigoid Market Report and Forecast 2024-2032

Bullous Pemphigoid Market Outlook

The bullous pemphigoid market size in the seven major markets is expected to grow at a CAGR of 17.7% during the forecast period of 2024-2032, likely to be driven by the rising incidence of geriatric population and increasing research activities to develop effective treatment solutions for patients across the major markets.

Bullous Pemphigoid Market Overview

Bullous pemphigoid is an autoimmune subepidermal blistering disease that causes large fluid-filled blisters on the skin. Common symptoms include large blisters that do not rupture easily when touched, itching skin, eczema, or a hive-like rashes. Mucous membrane involvement may occur in 10-40% of the patients. In the United States, annual incidence is 6 to 13 new cases per million people while Central Europe witnesses 12 to 13 new cases per million.  The incidence is similar in males and females; however, pregnant women are prone to get affected by a bullous pemphigoid variant, known as pemphigoid gestationis (PG). It develops in the later stages of the pregnancy (mostly second or third trimester) and has an estimated incidence of 1 case in 50,000 to 60,000 pregnancies.

The bullous pemphigoid market demand is directly impacted by the growing geriatric population as the condition is prevalent in the older generation, especially individuals aged 60 years or above. While the actual cause is unknown, bullous pemphigoid may be triggered by some medications, ultraviolet light therapy, and radiation as well.

Rising Number of Drugs under Investigation for Effective Treatment

In September 2023, the results of a study conducted at the National Autoimmune Bullous Diseases Cooperative Group of China revealed that Dupilumab  treatment helped in easing bullous pemphigoid symptoms. Inflammation of TH2 is a well-known factor for disease pathogenesis and Dupilumab works by blocking IL-4Rα to downregulate a TH2-related signal pathway. With the help of this mechanism, the drug has aided disease control by 87% within 4 weeks of treatment initiation. The increasing number of drugs under clinical investigation are a key indicator of bullous pemphigoid market growth.

Rising Adoption of Combination Therapies

With increasing advancements in drug and antibody development, and better understanding of the disease on a genetic level, novel drugs are being investigated to address a wider range of symptoms and offer personalized treatment to patients. Consequently, the application of combination therapies is one of the major bullous pemphigoid market trends. In November 2023, research conducted at the Department of Dermatology at the University of California revealed that Rituximab (RTX) and omalizumab (OMZ)  combination treatment demonstrated promising results on patients by reducing severe symptoms.

Increased Research on Disease Pathogenesis to Meet the Rising Bullous Pemphigoid Market Demand

Over 50% of the untreated bullous pemphigoid patients exhibit rising levels of blood eosinophils, making eosinophil infiltration a common characteristic of skin lesions. As a result, there has been significant emphasis on bringing effective solutions that treat the complications associated with the condition. In such cases, Bertilimumab , a humanized monoclonal antibody targeting eotaxin-1, is the latest drug being investigated for treating the condition. Simultaneously, Nemolizumab is also being considered as a potential medication to treat bullous pemphigoid in the future.

Surge in Research Activities to Offer Treatment for Prolonged and Treatment Resistant Symptoms

Bullous pemphigoid treatment is tailored on the basis of the severity of the condition and the patient’s history. The advancements in diagnostic technologies with improved histological evaluations also bolster the bullous pemphigoid market share. Oral steroids and systemic corticosteroids are the standard therapeutic options used. For patients with prolonged and resistant disease, long-term steroid treatment with a steroid-sparing immunomodulatory agent, such as tetracycline, intravenous immunoglobulin (IVIG), nicotinamide or dapsone, or immunosuppressive medications is administered.

Bullous Pemphigoid Market Segmentation

Market Breakup by Treatment Type

• Tablets

• Capsules
• Injectable
• Other

Market Breakup by Diagnosis

• Skin Biopsy

• Physical Examination

• Blood Test

Market by Drug Type

• Immunosuppressant Medication

• Steroids

• Antibiotics and Antiseptics

• Pain Relief Medication

Market Breakup by Route of Administration

• Oral

• Parenteral

• Others

Market Breakup by End User

• Hospitals

• Specialty Clinics

• Others

Market Breakup by Region

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom

• Japan

Bullous Pemphigoid Market Regional Analysis

In the forecast period, the United States is expected to lead the bullous pemphigoid market share, which can be attributed to higher incidence of neurological disorders such as stroke and dementia. The existence of key healthcare companies and a well-informed healthcare professional staff also adds significant value to the market. Several pharmaceutical companies are currently expanding their product portfolios to offer improved solutions to patients.

With a higher prevalence of geriatric population, Europe is another major market for bullous pemphigoid. With a robust healthcare infrastructure, the region is home to some influential academics and research institutions which contribute to the latest enhancements in treatment development. In addition, partnerships between firms and universities are also leading to increased market size.

Japan is one of the leading markets in the Asia Pacific region, based on value. However, emerging economies such as India, China, and South Korea are also projected to witness a substantial boost in the bullous pemphigoid market value in upcoming years. The increasing emphasis on offering improved healthcare services and development in medical infrastructure is one of the key reasons for growth. Owing to the easy availability of resources and noteworthy academic potential, various companies are investing in building research facilities to develop effective therapies for patients.

Bullous Pemphigoid Market: Competitor Landscape

In July 2022, Almirall, S.A. (ALM)  launched an open innovation platform to establish collaborations in dermatological research. The initiative was based on inviting advanced therapies, small molecules, and biologics for rare dermatological indications such as pemphigus vulgaris and bullous pemphigoid, among others. The market is witnessing a similar trend of growth as major companies are stepping up to offer funds and partnerships to innovative solutions.

The key features of the bullous pemphigoid market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Almirall

• Pfizer Inc.

• Greenstone LLC

• F. Hoffmann-La Roche Ltd

• SiriusLabs

• Teva Pharmaceutical Industries Ltd

• Astellas Pharma Inc.

• Aegis Lifesciences Pvt. Ltd

• Novartis AG

• Mylan N.V.

• Baxter

• Bayer AG

• Omega Laboratories

• Merck KGaA.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report